메뉴 건너뛰기




Volumn 4 FEB, Issue , 2013, Pages

Erlotinib resistance in lung cancer: Current progress and future perspectives

Author keywords

Drug resistance; Erlotinib; Lung cancer; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; AMRUBICIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BELOTECAN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; GEFITINIB; MICRORNA; NAVELBINE; NERATINIB; OBLIMERSEN; PACLITAXEL; PEMETREXED; PICOPLATIN; POZIOTINIB; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR INHIBITOR; VINFLUNINE;

EID: 84881095514     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00015     Document Type: Review
Times cited : (53)

References (112)
  • 1
    • 32944468708 scopus 로고    scopus 로고
    • Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
    • Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12, 878-887.
    • (2006) Clin. Cancer Res , vol.12 , pp. 878-887
    • Antonia, S.J.1    Mirza, N.2    Fricke, I.3    Chiappori, A.4    Thompson, P.5    Williams, N.6
  • 2
    • 34347379142 scopus 로고    scopus 로고
    • Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
    • Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., et al. (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst. 99, 847-857.
    • (2007) J. Natl. Cancer Inst. , vol.99 , pp. 847-857
    • Ardizzoni, A.1    Boni, L.2    Tiseo, M.3    Fossella, F.V.4    Schiller, J.H.5    Paesmans, M.6
  • 3
    • 74949133978 scopus 로고    scopus 로고
    • American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli, C. G., Baker, S. Jr., Temin, S., Pao, W., Aliff, T., Brahmer, J., et al. (2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27, 6251-6266.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 6251-6266
    • Azzoli, C.G.1    Baker Jr, S.2    Temin, S.3    Pao, W.4    Aliff, T.5    Brahmer, J.6
  • 4
    • 80053639884 scopus 로고    scopus 로고
    • 2011 Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli, C. G., Temin, S., Aliff, T., Baker, S. Jr., Brahmer, J., Johnson, D. H., et al. (2011). 2011 Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Oncol. Pract. 29, 3825-3831.
    • (2011) J. Oncol. Pract. , vol.29 , pp. 3825-3831
    • Azzoli, C.G.1    Temin, S.2    Aliff, T.3    Baker Jr, S.4    Brahmer, J.5    Johnson, D.H.6
  • 5
    • 61549087775 scopus 로고    scopus 로고
    • Cisplatin: a review of toxicities and therapeutic applications
    • Barabas, K., Milner, R., Lurie, D., and Adin, C. (2008). Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 6, 1-18.
    • (2008) Vet. Comp. Oncol. , vol.6 , pp. 1-18
    • Barabas, K.1    Milner, R.2    Lurie, D.3    Adin, C.4
  • 6
    • 77958067346 scopus 로고    scopus 로고
    • Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer
    • Batus, M., Fidler, M. J., and Bonomi, P. D. (2010). Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther 10, 1589-1599.
    • (2010) Expert Rev Anticancer Ther , vol.10 , pp. 1589-1599
    • Batus, M.1    Fidler, M.J.2    Bonomi, P.D.3
  • 7
    • 34250345258 scopus 로고    scopus 로고
    • EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms
    • Baumann, M., Krause, M., Dikomey, E., Dittmann, K., Dorr, W., Kasten-Pisula, U., et al. (2007). EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother. Oncol. 83, 238-248.
    • (2007) Radiother. Oncol. , vol.83 , pp. 238-248
    • Baumann, M.1    Krause, M.2    Dikomey, E.3    Dittmann, K.4    Dorr, W.5    Kasten-Pisula, U.6
  • 8
    • 0037248811 scopus 로고    scopus 로고
    • The physiologic evaluation of patients with lung cancer being considered for resectional surgery
    • Beckles, M. A., Spiro, S. G., Colice, G. L., and Rudd, R. M. (2003). The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 123, 105S-114S.
    • (2003) Chest 123, 105S-
    • Beckles, M.A.1    Spiro, S.G.2    Colice, G.L.3    Rudd, R.M.4
  • 10
    • 0034777482 scopus 로고    scopus 로고
    • Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival
    • Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., et al. (2001). Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. 7, 1850-1855.
    • (2001) Clin. Cancer Res. , vol.7 , pp. 1850-1855
    • Brabender, J.1    Danenberg, K.D.2    Metzger, R.3    Schneider, P.M.4    Park, J.5    Salonga, D.6
  • 11
    • 84871998076 scopus 로고    scopus 로고
    • An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    • Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., et al. (2013). An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290.
    • (2013) Clin. Cancer Res. , vol.19 , pp. 279-290
    • Byers, L.A.1    Diao, L.2    Wang, J.3    Saintigny, P.4    Girard, L.5    Peyton, M.6
  • 12
    • 77953541527 scopus 로고    scopus 로고
    • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    • Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczesna, A., Juhasz, E., et al. (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11, 521-529.
    • (2010) Lancet Oncol , vol.11 , pp. 521-529
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3    Cicenas, S.4    Szczesna, A.5    Juhasz, E.6
  • 14
    • 0033549356 scopus 로고    scopus 로고
    • Acute pain
    • Carr, D. B., and Goudas, L. C. (1999). Acute pain. Lancet 353, 2051-2058.
    • (1999) Lancet , vol.353 , pp. 2051-2058
    • Carr, D.B.1    Goudas, L.C.2
  • 15
    • 84859100127 scopus 로고    scopus 로고
    • Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
    • Cha, M. Y., Lee, K. O., Kim, M., Song, J. Y., Lee, K. H., Park, J., et al. (2012). Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int. J. Cancer 130, 2445-2454.
    • (2012) Int. J. Cancer , vol.130 , pp. 2445-2454
    • Cha, M.Y.1    Lee, K.O.2    Kim, M.3    Song, J.Y.4    Lee, K.H.5    Park, J.6
  • 16
    • 84873676278 scopus 로고    scopus 로고
    • Update of research on drug resistance in small cell lung cancer chemotherapy
    • Chen, Y. T., Feng, B., and Chen, L. B. (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac. J. Cancer Prev. 13, 3577-3581.
    • (2012) Asian Pac. J. Cancer Prev. , vol.13 , pp. 3577-3581
    • Chen, Y.T.1    Feng, B.2    Chen, L.B.3
  • 17
    • 17144371349 scopus 로고    scopus 로고
    • Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)
    • Chinnaiyan, P., Huang, S., Vallabhaneni, G., Armstrong, E., Varambally, S., Tomlins, S. A., et al. (2005). Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65, 3328-3335.
    • (2005) Cancer Res , vol.65 , pp. 3328-3335
    • Chinnaiyan, P.1    Huang, S.2    Vallabhaneni, G.3    Armstrong, E.4    Varambally, S.5    Tomlins, S.A.6
  • 18
  • 19
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    • Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., et al. (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374, 1432-1440.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3    Kim, J.H.4    Krzakowski, M.5    Laack, E.6
  • 20
    • 84866154541 scopus 로고    scopus 로고
    • A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
    • Clement-Duchene, C., Natale, R. B., Jahan, T., Krupitskaya, Y., Osarogiagbon, R., Sanborn, R. E., et al. (2012). A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer 78, 57-62.
    • (2012) Lung Cancer , vol.78 , pp. 57-62
    • Clement-Duchene, C.1    Natale, R.B.2    Jahan, T.3    Krupitskaya, Y.4    Osarogiagbon, R.5    Sanborn, R.E.6
  • 21
    • 0013825447 scopus 로고
    • The stimulation of epidermal proliferation by a specific protein (EGF)
    • Cohen, S. (1965). The stimulation of epidermal proliferation by a specific protein (EGF). Dev. Biol. 12, 394-407.
    • (1965) Dev. Biol. , vol.12 , pp. 394-407
    • Cohen, S.1
  • 24
    • 22144461002 scopus 로고    scopus 로고
    • miRNAs, cancer, and stem cell division
    • Croce, C. M., and Calin, G. A. (2005). miRNAs, cancer, and stem cell division. Cell 122, 6-7.
    • (2005) Cell , vol.122 , pp. 6-7
    • Croce, C.M.1    Calin, G.A.2
  • 25
    • 79955505489 scopus 로고    scopus 로고
    • Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells
    • Diep, C. H., Munoz, R. M., Choudhary, A., Von Hoff, D. D., and Han, H. (2011). Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin. Cancer Res. 17, 2744-2756.
    • (2011) Clin. Cancer Res. , vol.17 , pp. 2744-2756
    • Diep, C.H.1    Munoz, R.M.2    Choudhary, A.3    Von Hoff, D.D.4    Han, H.5
  • 26
    • 77953362931 scopus 로고    scopus 로고
    • New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    • Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., and Bunn, P. A. Jr. (2010). New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69, 1-12.
    • (2010) Lung Cancer , vol.69 , pp. 1-12
    • Doebele, R.C.1    Oton, A.B.2    Peled, N.3    Camidge, D.R.4    Bunn Jr, P.A.5
  • 27
    • 0036645063 scopus 로고    scopus 로고
    • Novel targets for lung cancer therapy: part I
    • Dy, G. K., and Adjei, A. A. (2002). Novel targets for lung cancer therapy: part I. J. Clin. Oncol. 20, 2881-2894.
    • (2002) J. Clin. Oncol. , vol.20 , pp. 2881-2894
    • Dy, G.K.1    Adjei, A.A.2
  • 29
    • 77951643141 scopus 로고    scopus 로고
    • Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
    • Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A., et al. (2010). Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29, 2346-2356.
    • (2010) Oncogene , vol.29 , pp. 2346-2356
    • Ercan, D.1    Zejnullahu, K.2    Yonesaka, K.3    Xiao, Y.4    Capelletti, M.5    Rogers, A.6
  • 30
    • 35649020283 scopus 로고    scopus 로고
    • MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
    • Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805-15810.
    • (2007) Proc. Natl. Acad. Sci. U. S. A. , vol.104 , pp. 15805-15810
    • Fabbri, M.1    Garzon, R.2    Cimmino, A.3    Liu, Z.4    Zanesi, N.5    Callegari, E.6
  • 31
    • 84861866572 scopus 로고    scopus 로고
    • The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC
    • Fabian, M. R., and Sonenberg, N. (2012). The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 19, 586-593.
    • (2012) Nat. Struct. Mol. Biol. , vol.19 , pp. 586-593
    • Fabian, M.R.1    Sonenberg, N.2
  • 32
    • 59149092945 scopus 로고    scopus 로고
    • Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    • Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., et al. (2009). Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 27, 591-598.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3    Loesch, D.M.4    Waterhouse, D.M.5    Bromund, J.L.6
  • 34
    • 84866600466 scopus 로고    scopus 로고
    • Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer
    • Foo, J., Chmielecki, J., Pao, W., and Michor, F. (2012). Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J. Thorac. Oncol. 7, 1583-1593.
    • (2012) J. Thorac. Oncol. , vol.7 , pp. 1583-1593
    • Foo, J.1    Chmielecki, J.2    Pao, W.3    Michor, F.4
  • 35
    • 0034095853 scopus 로고    scopus 로고
    • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
    • Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., et al. (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J. Clin. Oncol. 18, 2354-2362.
    • (2000) The TAX 320 non-small cell lung cancer study group. J. Clin. Oncol. , vol.18 , pp. 2354-2362
    • Fossella, F.V.1    DeVore, R.2    Kerr, R.N.3    Crawford, J.4    Natale, R.R.5    Dunphy, F.6
  • 36
    • 79960986318 scopus 로고    scopus 로고
    • Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
    • Giaccone, G., and Wang, Y. (2011). Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat. Rev. 37, 456-464.
    • (2011) Cancer Treat. Rev. , vol.37 , pp. 456-464
    • Giaccone, G.1    Wang, Y.2
  • 37
    • 84869499839 scopus 로고    scopus 로고
    • Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
    • Goldman, J. W., Laux, I., Chai, F., Savage, R. E., Ferrari, D., Garmey, E. G., et al. (2012). Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 118, 5903-5911.
    • (2012) Cancer , vol.118 , pp. 5903-5911
    • Goldman, J.W.1    Laux, I.2    Chai, F.3    Savage, R.E.4    Ferrari, D.5    Garmey, E.G.6
  • 38
    • 84882455547 scopus 로고    scopus 로고
    • HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
    • doi:10.1038/onc.2012.396
    • Gusenbauer, S., Vlaicu, P., and Ullrich, A. (2012). HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene. doi:10.1038/onc.2012.396
    • (2012) Oncogene
    • Gusenbauer, S.1    Vlaicu, P.2    Ullrich, A.3
  • 39
    • 0034861227 scopus 로고    scopus 로고
    • Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors
    • Hanauske, A. R., Chen, V., Paoletti, P., and Niyikiza, C. (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6, 363-373.
    • (2001) Oncologist , vol.6 , pp. 363-373
    • Hanauske, A.R.1    Chen, V.2    Paoletti, P.3    Niyikiza, C.4
  • 40
    • 0037758126 scopus 로고    scopus 로고
    • Morphine and alternative opioids in cancer pain: the EAPC recommendations
    • Hanks, G. W., Conno, F., Cherny, N., Hanna, M., Kalso, E., McQuay, H. J., et al. (2001). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 84, 587-593.
    • (2001) Br. J. Cancer , vol.84 , pp. 587-593
    • Hanks, G.W.1    Conno, F.2    Cherny, N.3    Hanna, M.4    Kalso, E.5    McQuay, H.J.6
  • 41
    • 42049104916 scopus 로고    scopus 로고
    • Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
    • Hann, C. L., Daniel, V. C., Sugar, E. A., Dobromilskaya, I., Murphy, S. C., Cope, L., et al. (2008). Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 68, 2321-2328.
    • (2008) Cancer Res , vol.68 , pp. 2321-2328
    • Hann, C.L.1    Daniel, V.C.2    Sugar, E.A.3    Dobromilskaya, I.4    Murphy, S.C.5    Cope, L.6
  • 44
    • 0042307325 scopus 로고    scopus 로고
    • The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    • Barbas CF3and Hynes N. E
    • Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas CF3and Hynes, N. E. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 100, 8933-8938.
    • (2003) Proc. Natl. Acad. Sci. U. S. A. , vol.100 , pp. 8933-8938
    • Holbro, T.1    Beerli, R.R.2    Maurer, F.3    Koziczak, M.4
  • 45
    • 61849140067 scopus 로고    scopus 로고
    • When apoptosis meets autophagy: deciding cell fate after trauma and sepsis
    • Hsieh, Y. C., Athar, M., and Chaudry, I. H. (2009). When apoptosis meets autophagy: deciding cell fate after trauma and sepsis. Trends. Mol. Med. 15, 129-138.
    • (2009) Trends. Mol. Med. , vol.15 , pp. 129-138
    • Hsieh, Y.C.1    Athar, M.2    Chaudry, I.H.3
  • 46
    • 18344390418 scopus 로고    scopus 로고
    • ERBB receptors and cancer: the complexity of targeted inhibitors
    • Hynes, N. E., and Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354.
    • (2005) Nat. Rev. Cancer , vol.5 , pp. 341-354
    • Hynes, N.E.1    Lane, H.A.2
  • 47
    • 33748074447 scopus 로고    scopus 로고
    • Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
    • Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., et al. (2006). Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854-7858.
    • (2006) Cancer Res , vol.66 , pp. 7854-7858
    • Inukai, M.1    Toyooka, S.2    Ito, S.3    Asano, H.4    Ichihara, S.5    Soh, J.6
  • 49
    • 77956185923 scopus 로고    scopus 로고
    • Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial
    • Jeong, J., Cho, B. C., Sohn, J. H., Choi, H. J., Kim, S. H., Lee, Y. J., et al. (2010). Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 70, 77-81.
    • (2010) Lung Cancer , vol.70 , pp. 77-81
    • Jeong, J.1    Cho, B.C.2    Sohn, J.H.3    Choi, H.J.4    Kim, S.H.5    Lee, Y.J.6
  • 50
    • 33747852920 scopus 로고    scopus 로고
    • Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy
    • Kelsey, C. R., Clough, R. W., and Marks, L. B. (2006). Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J. 12, 283-288.
    • (2006) Cancer J , vol.12 , pp. 283-288
    • Kelsey, C.R.1    Clough, R.W.2    Marks, L.B.3
  • 51
    • 32544451475 scopus 로고    scopus 로고
    • Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling
    • Khanzada, U. K., Pardo, O. E., Meier, C., Downward, J., Seckl, M. J., and Arcaro, A. (2006). Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 25, 877-887.
    • (2006) Oncogene , vol.25 , pp. 877-887
    • Khanzada, U.K.1    Pardo, O.E.2    Meier, C.3    Downward, J.4    Seckl, M.J.5    Arcaro, A.6
  • 52
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    • Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y. L., et al. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372, 1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3    Socinski, M.A.4    Gervais, R.5    Wu, Y.L.6
  • 53
    • 84922685314 scopus 로고    scopus 로고
    • Lung cancer: microRNA and target database
    • Kiran, C., and Deepika, P. (2012). Lung cancer: microRNA and target database. Zhongguo Fei Ai Za Zhi 15, 429-434.
    • (2012) Zhongguo Fei Ai Za Zhi , vol.15 , pp. 429-434
    • Kiran, C.1    Deepika, P.2
  • 54
    • 80052651609 scopus 로고    scopus 로고
    • Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer
    • Kosaka, T., Yamaki, E., Mogi, A., and Kuwano, H. (2011). Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J. Biomed. Biotechnol. 2011, 165-214.
    • (2011) J. Biomed. Biotechnol. , vol.2011 , pp. 165-214
    • Kosaka, T.1    Yamaki, E.2    Mogi, A.3    Kuwano, H.4
  • 55
    • 82355190618 scopus 로고    scopus 로고
    • The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer
    • Kwak, E. (2011). The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist 16, 1498-1507.
    • (2011) Oncologist , vol.16 , pp. 1498-1507
    • Kwak, E.1
  • 57
    • 40249114881 scopus 로고    scopus 로고
    • Lee, S. M., James, L., Buchler, T., Snee, M., Ellis, P., and Hackshaw, A. (2008). Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 59, 364-368.
    • (2008) , vol.59 , pp. 364-368
    • Lee, S.M.1    James, L.2    Buchler, T.3    Snee, M.4    Ellis, P.5    Hackshaw, A.6
  • 58
    • 84870888770 scopus 로고    scopus 로고
    • Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line
    • Leighl, N. B. (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr. Oncol. 19, S52-S58.
    • (2012) Curr. Oncol. , vol.19
    • Leighl, N.B.1
  • 60
    • 84879031393 scopus 로고    scopus 로고
    • doi:10.3389/fonc.2012.00031
    • Mehta, V. K. (2012). Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. Front. Oncol. 2:31. doi:10.3389/fonc.2012.00031
    • (2012) , vol.2
    • Mehta, V.K.1
  • 61
    • 84865988616 scopus 로고    scopus 로고
    • doi:10.1186/1471-2407-12-296
    • Minami, S., Kijima, T., Takahashi, R., Kida, H., Nakatani, T., Hamaguchi, M., et al. (2012). Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. BMC Cancer 12:296. doi:10.1186/1471-2407-12-296
    • (2012)
    • Minami, S.1    Kijima, T.2    Takahashi, R.3    Kida, H.4    Nakatani, T.5    Hamaguchi, M.6
  • 62
    • 23844491524 scopus 로고    scopus 로고
    • Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
    • Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., et al. (2005). Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97, 1185-1194.
    • (2005) J. Natl. Cancer Inst. , vol.97 , pp. 1185-1194
    • Mukohara, T.1    Engelman, J.A.2    Hanna, N.H.3    Yeap, B.Y.4    Kobayashi, S.5    Lindeman, N.6
  • 63
    • 84859795661 scopus 로고    scopus 로고
    • Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
    • Murakami, H., Tamura, T., Takahashi, T., Nokihara, H., Naito, T., Nakamura, Y., et al. (2012). Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother. Pharmacol. 69, 891-899.
    • (2012) Cancer Chemother. Pharmacol. , vol.69 , pp. 891-899
    • Murakami, H.1    Tamura, T.2    Takahashi, T.3    Nokihara, H.4    Naito, T.5    Nakamura, Y.6
  • 64
    • 84860400336 scopus 로고    scopus 로고
    • Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer
    • Nair, B. S., Bhanderi, V., and Jafri, S. H. (2011). Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. Clin. Med. Insights Oncol. 5, 223-234.
    • (2011) Clin. Med. Insights Oncol. , vol.5 , pp. 223-234
    • Nair, B.S.1    Bhanderi, V.2    Jafri, S.H.3
  • 65
    • 84866775213 scopus 로고    scopus 로고
    • First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    • Nguyen, K. S., and Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics 6, 337-345.
    • (2012) Biologics , vol.6 , pp. 337-345
    • Nguyen, K.S.1    Neal, J.W.2
  • 67
    • 84873835896 scopus 로고    scopus 로고
    • Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer
    • Nurwidya, F., Takahashi, F., Murakami, A., and Takahashi, K. (2012). Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res. Treat. 44, 151-156.
    • (2012) Cancer Res. Treat. , vol.44 , pp. 151-156
    • Nurwidya, F.1    Takahashi, F.2    Murakami, A.3    Takahashi, K.4
  • 68
    • 84860319366 scopus 로고    scopus 로고
    • Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance
    • Ogawa, T., Liggett, T. E., Melnikov, A. A., Monitto, C. L., Kusuke, D., Shiga, K., et al. (2012). Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle 11, 1656-1663.
    • (2012) Cell Cycle , vol.11 , pp. 1656-1663
    • Ogawa, T.1    Liggett, T.E.2    Melnikov, A.A.3    Monitto, C.L.4    Kusuke, D.5    Shiga, K.6
  • 69
    • 33847276516 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan
    • Ohe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., et al. (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann. Oncol. 18, 317-323.
    • (2007) Ann. Oncol. , vol.18 , pp. 317-323
    • Ohe, Y.1    Ohashi, Y.2    Kubota, K.3    Tamura, T.4    Nakagawa, K.5    Negoro, S.6
  • 70
    • 33748435058 scopus 로고    scopus 로고
    • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    • Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V., et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991.
    • (2006) N. Engl. J. Med. , vol.355 , pp. 983-991
    • Olaussen, K.A.1    Dunant, A.2    Fouret, P.3    Brambilla, E.4    Andre, F.5    Haddad, V.6
  • 72
    • 84870507634 scopus 로고    scopus 로고
    • Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
    • Orzaez, M., Guevara, T., Sancho, M., and Perez-Paya, E. (2012). Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. Cell Death Dis. 3, e415.
    • (2012) Cell Death Dis , vol.3
    • Orzaez, M.1    Guevara, T.2    Sancho, M.3    Perez-Paya, E.4
  • 73
    • 80052437758 scopus 로고    scopus 로고
    • New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    • Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., and Pao, W. (2011). New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17, 5530-5537.
    • (2011) Clin. Cancer Res. , vol.17 , pp. 5530-5537
    • Oxnard, G.R.1    Arcila, M.E.2    Chmielecki, J.3    Ladanyi, M.4    Miller, V.A.5    Pao, W.6
  • 74
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    • Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3    Tracy, S.4    Greulich, H.5    Gabriel, S.6
  • 75
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311.
    • (2004) Proc. Natl. Acad. Sci. U. S. A. , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3    Doherty, J.4    Politi, K.5    Sarkaria, I.6
  • 76
    • 2442562698 scopus 로고    scopus 로고
    • Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells
    • Partovian, C., and Simons, M. (2004). Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell. Signal. 16, 951-957.
    • (2004) Cell. Signal. , vol.16 , pp. 951-957
    • Partovian, C.1    Simons, M.2
  • 77
    • 84875445089 scopus 로고    scopus 로고
    • Targeting apoptosis pathways in lung cancer
    • doi:10.1016/j.canlet.2010.09.012
    • Pore, M. M., Hiltermann, T. J., and Kruyt, F. A. (2010). Targeting apoptosis pathways in lung cancer. Cancer Lett. doi:10.1016/j.canlet.2010.09.012
    • (2010) Cancer Lett
    • Pore, M.M.1    Hiltermann, T.J.2    Kruyt, F.A.3
  • 78
    • 33646371709 scopus 로고    scopus 로고
    • Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective
    • Roberti, A., La Sala, D., and Cinti, C. (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J. Cell. Physiol. 207, 571-581.
    • (2006) J. Cell. Physiol. , vol.207 , pp. 571-581
    • Roberti, A.1    La Sala, D.2    Cinti, C.3
  • 79
    • 77956265766 scopus 로고    scopus 로고
    • Small cell lung cancer: past, present, and future
    • Rodriguez, E., and Lilenbaum, R. C. (2010). Small cell lung cancer: past, present, and future. Curr. Oncol. Rep. 12, 327-334.
    • (2010) Curr. Oncol. Rep. , vol.12 , pp. 327-334
    • Rodriguez, E.1    Lilenbaum, R.C.2
  • 80
    • 1842562213 scopus 로고    scopus 로고
    • Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    • Rudin, C. M., Kozloff, M., Hoffman, P. C., Edelman, M. J., Karnauskas, R., Tomek, R., et al. (2004). Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J. Clin. Oncol. 22, 1110-1117.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 1110-1117
    • Rudin, C.M.1    Kozloff, M.2    Hoffman, P.C.3    Edelman, M.J.4    Karnauskas, R.5    Tomek, R.6
  • 81
    • 0030980781 scopus 로고    scopus 로고
    • Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression
    • Rusch, V., Klimstra, D., Venkatraman, E., Pisters, P. W., Langenfeld, J., and Dmitrovsky, E. (1997). Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3, 515-522.
    • (1997) Clin. Cancer Res. , vol.3 , pp. 515-522
    • Rusch, V.1    Klimstra, D.2    Venkatraman, E.3    Pisters, P.W.4    Langenfeld, J.5    Dmitrovsky, E.6
  • 82
    • 84865417560 scopus 로고    scopus 로고
    • Recent advances in non-small cell lung cancer biology and clinical management
    • Saintigny, P., and Burger, J. A. (2012). Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med. 13, 287-297.
    • (2012) Discov. Med. , vol.13 , pp. 287-297
    • Saintigny, P.1    Burger, J.A.2
  • 83
    • 0028955388 scopus 로고
    • Epidermal growth factor-related peptides and their receptors in human malignancies
    • Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232.
    • (1995) Crit. Rev. Oncol. Hematol. , vol.19 , pp. 183-232
    • Salomon, D.S.1    Brandt, R.2    Ciardiello, F.3    Normanno, N.4
  • 84
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550.
    • (2006) N. Engl. J. Med. , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 86
    • 84866745062 scopus 로고    scopus 로고
    • The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer
    • Shapiro, M. (2012). The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer. Cleve. Clin. J. Med. 79(Suppl. 1), eS42-S45.
    • (2012) Cleve. Clin. J. Med. , vol.79 , Issue.SUPPL. 1
    • Shapiro, M.1
  • 87
    • 33847323129 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in lung cancer
    • Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181.
    • (2007) Nat. Rev. Cancer , vol.7 , pp. 169-181
    • Sharma, S.V.1    Bell, D.W.2    Settleman, J.3    Haber, D.A.4
  • 89
    • 84857698541 scopus 로고    scopus 로고
    • Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
    • Shimizu, S., Takehara, T., Hikita, H., Kodama, T., Tsunematsu, H., Miyagi, T., et al. (2012). Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int. J. Cancer 131, 548-557.
    • (2012) Int. J. Cancer , vol.131 , pp. 548-557
    • Shimizu, S.1    Takehara, T.2    Hikita, H.3    Kodama, T.4    Tsunematsu, H.5    Miyagi, T.6
  • 91
    • 77950678272 scopus 로고    scopus 로고
    • Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
    • Sierra, J. R., Cepero, V., and Giordano, S. (2010). Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75.
    • (2010) Mol. Cancer , vol.9 , pp. 75
    • Sierra, J.R.1    Cepero, V.2    Giordano, S.3
  • 93
    • 0025822201 scopus 로고
    • The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial
    • Skinner, D. G., Daniels, J. R., Russell, C. A., Lieskovsky, G., Boyd, S. D., Nichols, P., et al. (1991). The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145, 459-464.
    • (1991) J. Urol. , vol.145 , pp. 459-464
    • Skinner, D.G.1    Daniels, J.R.2    Russell, C.A.3    Lieskovsky, G.4    Boyd, S.D.5    Nichols, P.6
  • 94
    • 79952704441 scopus 로고    scopus 로고
    • EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
    • Spicer, J. F., and Rudman, S. M. (2010). EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol 5, 245-255.
    • (2010) Target Oncol , vol.5 , pp. 245-255
    • Spicer, J.F.1    Rudman, S.M.2
  • 95
    • 78649916542 scopus 로고    scopus 로고
    • Targeting the epidermal growth factor receptor in non-small cell lung cancer
    • Steins, M. B., Reinmuth, N., Bischoff, H., Kindermann, M., and Thomas, M. (2010). Targeting the epidermal growth factor receptor in non-small cell lung cancer. Onkologie 33, 704-709.
    • (2010) Onkologie , vol.33 , pp. 704-709
    • Steins, M.B.1    Reinmuth, N.2    Bischoff, H.3    Kindermann, M.4    Thomas, M.5
  • 96
    • 61549108338 scopus 로고    scopus 로고
    • EGFR T790M mutation: a double role in lung cancer cell survival? J
    • Suda, K., Onozato, R., Yatabe, Y., and Mitsudomi, T. (2009). EGFR T790M mutation: a double role in lung cancer cell survival? J. Thorac. Oncol. 4, 1-4.
    • (2009) Thorac. Oncol. , vol.4 , pp. 1-4
    • Suda, K.1    Onozato, R.2    Yatabe, Y.3    Mitsudomi, T.4
  • 97
    • 77649203360 scopus 로고    scopus 로고
    • Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203)
    • Takeda, K., Hida, T., Sato, T., Ando, M., Seto, T., Satouchi, M., et al. (2010). Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J. Clin. Oncol. 28, 753-760.
    • (2010) J. Clin. Oncol. , vol.28 , pp. 753-760
    • Takeda, K.1    Hida, T.2    Sato, T.3    Ando, M.4    Seto, T.5    Satouchi, M.6
  • 98
    • 79959605918 scopus 로고    scopus 로고
    • Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
    • Tang, C. H., Parham, C., Shocron, E., McMahon, G., and Patel, N. (2011). Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother. Pharmacol. 67, 1389-1400.
    • (2011) Cancer Chemother. Pharmacol. , vol.67 , pp. 1389-1400
    • Tang, C.H.1    Parham, C.2    Shocron, E.3    McMahon, G.4    Patel, N.5
  • 99
    • 34248334117 scopus 로고    scopus 로고
    • The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy
    • Tortora, G., Gelardi, T., Ciardiello, F., and Bianco, R. (2007). The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int. J. Biol. Markers 22, S46-S52.
    • (2007) Int. J. Biol. Markers , vol.22
    • Tortora, G.1    Gelardi, T.2    Ciardiello, F.3    Bianco, R.4
  • 100
    • 70449715208 scopus 로고    scopus 로고
    • Cisplatin overdose: toxicities and management
    • Tsang, R. Y., Al-Fayea, T., and Au, H. J. (2009). Cisplatin overdose: toxicities and management. Drug Saf. 32, 1109-1122.
    • (2009) Drug Saf , vol.32 , pp. 1109-1122
    • Tsang, R.Y.1    Al-Fayea, T.2    Au, H.J.3
  • 101
    • 84871342163 scopus 로고    scopus 로고
    • Combined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
    • Wang, M., Zhao, J., Zhang, L. M., Li, H., Yu, J. P., Ren, X. B., et al. (2012). Combined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. J. Cancer Res. Clin. Oncol. 138, 2069-2077.
    • (2012) J. Cancer Res. Clin. Oncol. , vol.138 , pp. 2069-2077
    • Wang, M.1    Zhao, J.2    Zhang, L.M.3    Li, H.4    Yu, J.P.5    Ren, X.B.6
  • 102
    • 23944515380 scopus 로고    scopus 로고
    • Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies
    • Weinberger, P. M., Yu, Z., Kowalski, D., Joe, J., Manger, P., Psyrri, A., et al. (2005). Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch. Otolaryngol. Head Neck Surg. 131, 707-711.
    • (2005) Arch. Otolaryngol. Head Neck Surg. , vol.131 , pp. 707-711
    • Weinberger, P.M.1    Yu, Z.2    Kowalski, D.3    Joe, J.4    Manger, P.5    Psyrri, A.6
  • 103
    • 44849091213 scopus 로고    scopus 로고
    • EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
    • Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., et al. (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 19, 1053-1059.
    • (2008) Ann. Oncol. , vol.19 , pp. 1053-1059
    • Weiss, G.J.1    Bemis, L.T.2    Nakajima, E.3    Sugita, M.4    Birks, D.K.5    Robinson, W.A.6
  • 104
    • 0032803586 scopus 로고    scopus 로고
    • Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase
    • Weiss, R. H., Ramirez, A., and Joo, A. (1999). Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. J. Am. Soc. Nephrol. 10, 1880-1890.
    • (1999) J. Am. Soc. Nephrol. , vol.10 , pp. 1880-1890
    • Weiss, R.H.1    Ramirez, A.2    Joo, A.3
  • 105
    • 77956268839 scopus 로고    scopus 로고
    • Understanding resistance to EGFR inhibitors-impact on future treatment strategies
    • Wheeler, D. L., Dunn, E. F., and Harari, P. M. (2010). Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7, 493-507.
    • (2010) Nat. Rev. Clin. Oncol. , vol.7 , pp. 493-507
    • Wheeler, D.L.1    Dunn, E.F.2    Harari, P.M.3
  • 106
    • 80053562740 scopus 로고    scopus 로고
    • Novel strategies for the treatment of small-cell lung carcinoma
    • William, W. N. Jr., and Glisson, B. S. (2011). Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 8, 611-619.
    • (2011) Nat. Rev. Clin. Oncol. , vol.8 , pp. 611-619
    • William Jr, W.N.1    Glisson, B.S.2
  • 107
    • 84866940771 scopus 로고    scopus 로고
    • Personalized targeted therapy for lung cancer
    • Wu, K., House, L., Liu, W., and Cho, W. C. (2012). Personalized targeted therapy for lung cancer. Int J Mol Sci 13, 11471-11496.
    • (2012) Int J Mol Sci , vol.13 , pp. 11471-11496
    • Wu, K.1    House, L.2    Liu, W.3    Cho, W.C.4
  • 108
    • 80053535498 scopus 로고    scopus 로고
    • Epithelial mesenchymal transition and lung cancer
    • Xiao, D., and He, J. (2010). Epithelial mesenchymal transition and lung cancer. J. Thorac. Dis. 2, 154-159.
    • (2010) J. Thorac. Dis. , vol.2 , pp. 154-159
    • Xiao, D.1    He, J.2
  • 109
    • 77957585027 scopus 로고    scopus 로고
    • Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
    • Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., et al. (2010). Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28, 3965-3972.
    • (2010) J. Clin. Oncol. , vol.28 , pp. 3965-3972
    • Yap, T.A.1    Vidal, L.2    Adam, J.3    Stephens, P.4    Spicer, J.5    Shaw, H.6
  • 110
    • 0034773992 scopus 로고    scopus 로고
    • The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities
    • Yarden, Y. (2001). The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8.
    • (2001) Eur. J. Cancer , vol.37 , Issue.SUPPL. 4
    • Yarden, Y.1
  • 112
    • 84873675746 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor trichostatin a enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line
    • Zhang, Q. C., Jiang, S. J., Zhang, S., and Ma, X. B. (2012). Histone deacetylase inhibitor trichostatin a enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac. J. Cancer Prev. 13, 3471-3476.
    • (2012) Asian Pac. J. Cancer Prev , vol.13 , pp. 3471-3476
    • Zhang, Q.C.1    Jiang, S.J.2    Zhang, S.3    Ma, X.B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.